$15,451.48 consulting Payment -- Johnson & Johnson to Dr. Heather Mitchell

Payment Details

AI-Powered Analysis of This Payment

The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.

This report details a payment of $15,451.48 made by Johnson & Johnson to Dr. Heather Mitchell, an Internal Medicine specialist in City, AZ, on January 29, 2026. The payment was for consulting services related to Kisqali, a medication manufactured by Johnson & Johnson. Consulting fees are common in the pharmaceutical industry, allowing companies to leverage physician expertise for product development, market research, and educational initiatives. The amount, while substantial, is not necessarily out of the ordinary for specialized consulting work, especially if it involved significant time commitment or expertise related to a specific drug like Kisqali, which is used in cancer treatment. Potential conflict of interest is a key consideration. When physicians receive payments from pharmaceutical companies whose products they may prescribe, there's a theoretical risk that these financial ties could influence prescribing decisions. However, it's crucial to understand that such payments do not automatically imply wrongdoing or that patient care has been compromised. Many physicians engage in these relationships to stay abreast of the latest medical advancements and contribute to the improvement of treatments. Dr. Mitchell's role as an Internal Medicine specialist means she treats a wide range of conditions, and her expertise might be valuable for understanding how a drug like Kisqali fits into broader patient care strategies. Comparing this payment to industry averages is complex, as consulting fees can vary widely based on the physician's reputation, the scope of work, and the specific drug or therapeutic area. However, payments in the thousands of dollars for consulting are not uncommon. Patients should view this information as a piece of the puzzle in understanding their doctor's professional activities. Transparency laws like the Sunshine Act aim to provide this visibility. It's important for patients to have open conversations with their doctors about any financial relationships to ensure trust and clarity in their healthcare journey. This payment, by itself, is a data point that warrants understanding within the broader context of medical practice and industry collaboration.

Patient Guidance: What This Payment Means for You

It's understandable to feel curious or concerned when you see a payment like this. The Sunshine Act aims to provide transparency, so you have the right to know about these relationships. First, remember that a payment doesn't automatically mean your doctor's decisions are biased. Many physicians consult to share their expertise and stay informed about new treatments. To understand this better, consider asking your doctor directly. You could say something like, "I saw on the Open Payments database that you received a consulting fee from Johnson & Johnson related to Kisqali. Could you tell me more about that work and how it informs your practice?" This opens a dialogue. Think about whether your doctor primarily prescribes Kisqali or if they discuss various treatment options. If they are open and explain their rationale for prescribing, it's a good sign. Payments for consulting or speaking are generally considered routine for many specialists. However, if your doctor seems defensive, dismissive, or if you have specific concerns about your treatment plan, it might warrant further discussion or a second opinion. The key is open communication and trusting your instincts.

Payment Context: Is This Amount Normal?

Internal Medicine is a broad specialty, and physicians in this field often engage with pharmaceutical companies. Payments for consulting can range from a few hundred to many thousands of dollars, depending on the physician's expertise, the duration of the consulting, and the specific project. While this $15,451 payment is on the higher end for a single consulting engagement, it's not exceptionally unusual for specialized advice. Approximately 40-50% of physicians in various specialties receive some form of payment from the industry annually, with consulting being a significant portion.

Regulatory Context: Sunshine Act Requirements

The Sunshine Act, part of the Affordable Care Act, requires pharmaceutical and medical device companies to report payments made to physicians and teaching hospitals. This specific payment, a consulting fee of $15,451.48, clearly exceeds the reporting threshold (which is generally $10 or more for covered payments). Such consulting arrangements are subject to standard reporting requirements. While not subject to special scrutiny beyond routine disclosure, these payments are closely watched by transparency advocates and can be reviewed by regulatory bodies if patterns of potential non-compliance emerge.

Related Topics

This payment is related to the following healthcare transparency topics:

• pharma-payments
• internal-medicine
• consulting-fees
• sunshine-act
• kisqali
• johnson-and-johnson
• conflict-of-interest

Understanding consulting Payments

Consulting payments are made when pharmaceutical companies hire physicians as advisors or consultants. This can include serving on advisory boards, providing expert medical opinions on drug development or marketing strategies, and reviewing clinical data. Consulting is one of the most common forms of pharmaceutical payment to physicians and can range from a few hundred dollars for a brief consultation to tens of thousands of dollars for ongoing advisory relationships.

Frequently Asked Questions About This Payment

Does my doctor take pharma money?

You can find out by visiting the Centers for Medicare & Medicaid Services (CMS) Open Payments database online. This public database lists payments made by drug and device companies to physicians and teaching hospitals. Simply search for your doctor's name. Seeing payments doesn't automatically mean your doctor is biased, but it provides transparency. It's a tool to foster informed conversations between you and your healthcare provider about their professional relationships and potential influences on treatment decisions.

Should I worry about this payment?

This specific payment of $15,451.48 for consulting related to Kisqali is a significant amount, but consulting fees for specialized medical advice are common. It's important to consider the context: Is your doctor an expert in oncology or internal medicine relevant to Kisqali's use? Do they openly discuss treatment options? While this payment warrants awareness, it doesn't automatically signal a problem. Worry is best channeled into constructive conversation with your doctor about their professional activities and your care plan.

What types of pharma payments are most concerning?

Payments that raise the most concern are often those that are less transparent or directly tied to prescribing specific drugs without clear justification. This includes large, recurring 'consulting' fees where the work isn't well-defined, 'speaker fees' for promotional events, or 'research grants' that primarily benefit the physician rather than advancing broad scientific knowledge. Payments for meals, travel, or gifts, while smaller, can also contribute to subtle biases. The key is understanding the nature and purpose of the payment.

How do I talk to my doctor about pharma relationships?

Approach the conversation calmly and curiously. You could start by saying, 'I'm trying to be more informed about my healthcare, and I saw on the Open Payments website that you've received payments from pharmaceutical companies. Could you help me understand what that involves?' Ask specific questions like, 'How do these relationships help you stay current with treatments?' or 'Does this influence how you choose medications for me?' Most doctors are willing to discuss these relationships if approached respectfully.

Is it legal for doctors to accept pharma payments?

Yes, it is legal for doctors to accept payments from pharmaceutical and medical device companies, provided these payments are accurately reported under the Sunshine Act. The Act requires companies to disclose payments for things like consulting, speaking, research, meals, and travel. The legality hinges on transparency and disclosure. The system aims to balance the need for industry collaboration and physician expertise with the public's right to know about potential conflicts of interest.

Does pharma money affect what my doctor prescribes?

Research suggests that financial relationships with pharmaceutical companies can, on average, influence prescribing patterns. Doctors who receive payments may be more likely to prescribe the company's drugs. However, this is a statistical trend, not a certainty for every individual doctor. Many factors influence prescribing decisions, including clinical evidence, patient needs, and physician experience. Transparency laws like the Sunshine Act aim to mitigate undue influence by making these relationships public.

How does this compare to other doctors in this specialty?

Internal Medicine is a broad field, and consulting payments can vary widely. While $15,451 is a substantial amount for a single consulting engagement, it falls within the range of payments seen for specialized expertise in areas like oncology (where Kisqali is used). Many Internal Medicine physicians receive payments, but the frequency and amount differ. This payment is higher than average for a single event but not exceptionally rare for significant consulting work within the specialty.

Related Reports

• View Dr. Heather Mitchell's full payment report
• Johnson & Johnson full spending report
• Browse all Internal Medicine payments
• Browse all payments in Arizona
• Search for other payments